Command Palette

Search for a command to run...

Preprint WatchStrongOctober 20th, 2026

Pharmacovigilance and Mechanistic Analysis of Adverse Reaction Differences Across EGFR Tyrosine Kinase Inhibitor Generations in Non-Small Cell Lung Cancer

Arojo, O.; Jones, A. M.

Generation-specific EGFR TKI toxicity profiles are mechanistically explained by the physicochemical and pharmacokinetic properties of each inhibitor, supporting property-based prediction of adverse reactions for EGFR-directed agents.

Strong contradiction

3 prior failures

Three or more documented clinical failures match this mechanism, or a Phase 3 efficacy failure is on record.

This preprint analyses generation-specific adverse drug reaction profiles for erlotinib, afatinib and osimertinib using WHO VigiAccess (88,662 case safety reports) and the UK MHRA Yellow Card scheme (752 reports), and argues that EGFR TKI physicochemical and pharmacokinetic properties give mechanistic plausibility to signals including erlotinib eye disorders (reporting odds ratio 4.33 in VigiAccess) and osimertinib pneumonitis (7.67). The Claidex graph holds three EGFR failures, and none of them failed on safety. tak-186-mvc-101-egfr-cd3-cobra-solid-tumors-phase1-2-efficacy-failure records an efficacy failure for an EGFR-directed T-cell engager in EGFR-expressing solid tumours, fpi-2107-egfr-cmet-nsclc-dosimetry-uptake-failure records a translational mismatch where tumour uptake did not follow target expression, and bg-60366-egfr-cdac-nsclc-strategic-shutdown records a sponsor decision. The flag is therefore about scope rather than contradiction. The preprint reasons from marketed small-molecule inhibitors whose on-target activity is established, so its mechanistic framework does not transfer to EGFR modalities that have repeatedly failed to convert target expression into tumour exposure or response. Reporting odds ratios from spontaneous databases carry confounding by indication, which the authors flag for the neoplasm-related signals, and the authors describe their own findings as hypothesis-generating. Programmes citing this work as support for EGFR tractability in new modalities should note that the three failures on file sit upstream of toxicity, at target engagement and at response.

Abstract excerpt

Background: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for EGFR-mutated non-small cell lung cancer (NSCLC) but have distinct toxicity profiles across generations. Aims: To investigate relationships between EGFR-TKI physicochemical, pharmacokinetic and pharmacological properties and drug-specific adverse drug reactions (ADRs) using national and global pharmacovigilance data. Methods: ADRs for erlotinib, afatinib and osimertinib were extracted from the UK MHRA Yellow Card scheme and WHO VigiAccess. Disproportionality analysis used reporting odds ratios (RORs). Signals were defined as ROR >2, lower 95% confidence interval >1 and >3 cases. Drug properties were curated from ChEMBL, emc, SmPC and EMA sources. Results: VigiAccess contained 88,662 individual case safety reports (163,619 ADRs) and Yellow Card contained 752 reports (1,814 ADRs). Four System Organ Class (SOC) signals were identified in VigiAccess and three in Yellow Card, with five additional Yellow Card Preferred Term signals. Eye disorders showed the strongest consistent association with erlotinib (VigiAccess ROR 4.33; Yellow Card ROR 4.18). Osimertinib was associated with pneumonitis (ROR 7.67) and pulmonary embolism (ROR 3.94). Afatinib showed psychiatric disorder signals in both databases (ROR 3.2-3.3) and diarrhoea (ROR 2.79). Neoplasm-related signals likely reflected confounding by indication. Conclusions: EGFR-TKIs demonstrate generation-specific pharmacovigilance profiles. Integration with drug properties supports mechanistic plausibility for several signals, while the atypical afatinib psychiatric association warrants further investigation. Findings are hypothesis-generating and require confirmation in controlled observational or mechanistic studies.

Matching Claidex post-mortems

3 of 3 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.